Sam***ara

Corporate Development

Éducation

Yale University

Yale University (2018 - 2020)

  • Degree: Master of Business Administration - MBA
  • Field of Study: Unknown Field
  • Description: Co-Founder & Editor, Yale Africa Startup Review Summer Associate, Vertex Pharmaceuticals Tsai Center for Innovative Thinking at Yale (Tsai CITY): Accelerator Portfolio Manager Venture Capital Intern, Bulldog Innovation Group, LLC

The College of Wooster (2010 - 2014)

  • Degree: Bachelor of Arts (B.A.)
  • Field of Study: Cell/Cellular and Molecular Biology
  • Description: Research Fellowship, Cystic Fibrosis Foundation Therapeutics Undergraduate Research Fellow, American Society for Microbiology Global Impact Fellow, Unite For Sight

Compétences :

Deal Execution, Strategic Communications, Search & Evaluation, Negotiation

Expérience professionnelle :

Corporate Development at Gilead Sciences

  • Location: San Francisco Bay Area
  • Duration: 2021-07 to Present
  • Description: Combining strong scientific expertise with strategic biotech business acumen to drive diligence and transactions. Technical diligence, deal structuring and contracting for both pre-clinical & clinical stage platforms & assets: mergers & acquisitions, research collaborations, licensing deals and investments. Management of Gilead's engagements with venture capital firms. Focused on next-gen platforms (wet lab & computational) with the potential to accelerate small molecule drug discovery, protein therapeutics, and emerging modalities for cancer, immunology and virology. Selected Deal Experience (Includes both transactional & scientific diligence) - Dragonfly Therapeutics; $300M upfront - License & Option, Multi-target - Tentarix Therapeutics; $66M upfront - Option to Acquire, Equity investment, Multi-target - Genesis Therapeutics; $35M upfront - Small Molecule Discovery, Generative AI, Multi-target - Cartography Biosciences; $20M upfront - Target Discovery, Single-cell Genomics, Multi-target - Terray Therapeutics; Undisclosed $ - Small Molecule Discovery, Nanotech + AI, Multi-target - A-Alpha Bio; Undisclosed $ - Large Molecule Discovery, Machine Learning/Synthetic Bio - AbTherx; Undisclosed $ - Antibody Discovery Platform - Biocytogen; Undisclosed $ - Antibody Discovery Platform

Co-Founder & Alumni Editor in Chief at Yale Africa Startup Review

  • Location:
  • Duration: 2021-03 to Present
  • Description: The Yale Africa Startup Review is a student and alumni-led initiative featuring founders and startups shaping the future of Africa with entrepreneurship. Our mission is to share stories of ingenuity and innovation to attract interested stakeholders to the African startup ecosystem. We engage with the continent’s most active & innovative venture capital firms and ecosystem partners. https://www.yasr.org/

Corporate Finance at Gilead Sciences

  • Location: Foster City, California, United States
  • Duration: 2020-08 to 2021-07
  • Description: Corporate risk governance & controls (financial, technology, business conduct & operational controls)

Researcher at Broad Institute of MIT and Harvard

  • Location:
  • Duration: 2014-08 to 2018-08
  • Description: Targeted therapies & drug delivery in T-cell Acute Lymphoblastic Leukemia (Published in the Journal of Experimental Medicine) Epigenetic resistance to cancer therapeutics in Neuroblastoma (Published in Cancer Cell) Blockade of gain-of-function mutations in NOTCH-driven liquid tumors (Published in Cell Chemical Biology) Targeted therapy & genomic characterization in Hepatosplenic T-cell Lymphoma (Published in Blood Advances) Targeted strategies for serine metabolism in Leukemia (Published - Leukemia, Nature Publishing) Epigenetic dependencies in T-Cell Acute Lymphoblastic Leukemia (Published - Cell Death & Disease, Nature Publishing)

Researcher at Dana-Farber Cancer Institute, Harvard Medical School

  • Location:
  • Duration: 2014-08 to 2018-08
  • Description: - Targeted therapies & drug delivery in T-cell Acute Lymphoblastic Leukemia (Published in the Journal of Experimental Medicine) - Epigenetic resistance to cancer therapeutics in Neuroblastoma (Published in Cancer Cell) - Blockade of gain-of-function mutations in NOTCH-driven liquid tumors (Published in Cell Chemical Biology) - Targeted therapy & genomic characterization in Hepatosplenic T-cell Lymphoma (Published in Blood Advances) - Targeted strategies for serine metabolism in Leukemia (Published - Leukemia, Nature Publishing) - Epigenetic dependencies in T-Cell Acute Lymphoblasitc Leukemia (Published - Cell Death & Disease, Nature Publishing)
Analyse de CV par IA

Rapport d'intelligence candidat

Analyse alimentée par l'IA du point de vue d'un directeur de recrutement américain — évaluant la continuité de carrière, la trajectoire de croissance et l'adéquation au poste.

Continuité de carrière et évaluation des risques

Employment GapMedium

There is an implied gap between 2018 and 2020 where no role is listed, which introduces moderate continuity risk. Overlaps in 2021 with Yale Africa Startup Review partially mitigate this concern by showing ongoing professional activity.

Industry ConsistencyLow

All roles are within life sciences and biotech, including research, pharma corporate functions, and startup ecosystem work, indicating strong industry consistency.

Tenure StabilityLow

Long-term engagements in academia (2014-2018) and stable progression within Gilead (2020-2021; 2021-Present) demonstrate solid tenure stability.

Education-Career MatchMedium

Education is listed as Yale University but degree field and level are not specified, which makes it harder to assess exact alignment with biotech deal-making roles.

Courbe de croissance de carrière

Researcher Entry
Broad Institute of MIT and Harvard
2014-08 to 2018-08
Researcher Lateral
Dana-Farber Cancer Institute, Harvard Medical School
2014-08 to 2018-08
Corporate Finance Lateral
Gilead Sciences
2020-08 to 2021-07
Co-Founder & Alumni Editor in Chief Lateral
Yale Africa Startup Review
2021-03 to Present
Corporate Development ↑ Promu
Gilead Sciences
2021-07 to Present
Évaluation :Samuel shows a clear upward arc: foundational scientific work followed by increasingly strategic, deal-focused roles in biotech, culminating in current leadership in corporate development. He appears well-positioned for senior director or VP-level BD roles, with potential for broader strategy leadership.

Rôles les mieux adaptés (Top 5)

1

Senior Director, Corporate Development98% adéquation

Proven track record leading diligence, deal structuring, and licensing in a top biotech/pharma company, with VC engagement experience and multi-asset portfolios.

2

Vice President, Corporate Development94% adéquation

Advanced execution capabilities, broad deal exposure from preclinical to clinical assets, and proven internal progression within Gilead.

3

Head of Strategic Partnerships (Biotech)91% adéquation

Strong deal execution and strategic communications background suits leadership of external partnerships and alliance management.

4

Director of Licensing & Alliances87% adéquation

Specialized licensing and alliance management focus aligns with portfolio expansion and cross-functional collaboration needs.

5

Vice President, Strategy & Corporate Development82% adéquation

Broader strategic remit combining BD, portfolio strategy, and market assessment; appropriate for organizations scaling biotech programs.

Découvrez AI Recruiter

Commencez à 0 $. Ne laissez pas vos concurrents obtenir l'avantage de l'IA en premier.

Rejoignez plus de 10 000 entreprises utilisant des solutions de recrutement basées sur l'IA pour automatiser votre processus d'embauche et économiser 80% du temps.

33% de réduction, plus que 48 heures !
Essayez l'IA gratuitement

Opération automatisée 24h/24 et 7j/7

Sélection des candidats par IA

Recrutement sans limites géographiques ou de fuseau horaire

Communication intelligente personnalisée

Évaluation automatisée de l'engagement des candidats

Imite et reproduit intelligemment votre style de recrutement

Garantie de remboursement de 4 mois

Assure la sécurité du compte LinkedIn